Evolent Health, Inc (NYSE:EVH – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $6.1607.
Several brokerages have recently weighed in on EVH. TD Cowen decreased their price target on Evolent Health from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday. Needham & Company LLC lifted their price objective on Evolent Health from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Truist Financial cut Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 target price on the stock. in a report on Tuesday, June 30th. Weiss Ratings lowered shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 21st. Finally, Citigroup restated a “sell” rating and issued a $6.75 price target (up from $5.50) on shares of Evolent Health in a research report on Thursday, July 23rd.
View Our Latest Analysis on EVH
Hedge Funds Weigh In On Evolent Health
Evolent Health Trading Down 3.5%
Shares of NYSE EVH opened at $3.19 on Friday. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.32 and a current ratio of 1.32. Evolent Health has a 52-week low of $2.10 and a 52-week high of $10.30. The firm has a 50 day moving average price of $4.82 and a two-hundred day moving average price of $3.74. The stock has a market cap of $358.25 million, a P/E ratio of -0.67 and a beta of 0.76.
Evolent Health (NYSE:EVH – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The technology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. Evolent Health had a negative net margin of 26.29% and a positive return on equity of 0.36%. The company had revenue of $496.25 million for the quarter, compared to analyst estimates of $534.00 million. During the same quarter in the previous year, the business earned $0.06 earnings per share. Evolent Health’s revenue was up 2.6% compared to the same quarter last year. As a group, equities analysts forecast that Evolent Health will post -0.16 EPS for the current year.
About Evolent Health
Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.
The company’s core offerings include care management solutions, population health analytics and clinical advisory services.
Featured Stories
- Five stocks we like better than Evolent Health
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.
